Updates are available Correction dated 2021-10-21
Click to view Correction: https://doi.org/10.1038/s41467-021-26492-5
-
Authors
Dumbović, Gabrijela https://orcid.org/0000-0002-1278-0273
Braunschweig, Ulrich https://orcid.org/0000-0001-6653-0926
Langner, Heera K.
Smallegan, Michael https://orcid.org/0000-0002-5919-6736
Biayna, Josep
Hass, Evan P.
Jastrzebska, Katarzyna https://orcid.org/0000-0003-3979-3186
Blencowe, Benjamin https://orcid.org/0000-0002-4461-0340
Cech, Thomas R. https://orcid.org/0000-0001-7338-3389
Caruthers, Marvin H.
Rinn, John L. https://orcid.org/0000-0002-7231-7539
- License Information
-
More Information
Article History
Received: 10 July 2020
Accepted: 7 April 2021
First Online: 3 June 2021
Change Date: 21 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-021-26492-5
Competing interests
: The authors declare no competing interests. T.R.C. is on the Merck board and is a consultant for Storm Therapeutics and Eikon Therapeutics.
